Protein binding of β-lactam antibiotics in critically Ill patients: can we successfully predict unbound concentrations? by Wong, Gloria et al.
Protein Binding of -Lactam Antibiotics in Critically Ill Patients: Can
We Successfully Predict Unbound Concentrations?
Gloria Wong,a Scott Briscoe,b Syamhanin Adnan,a Brett McWhinney,b Jacobus Ungerer,b Jeffrey Lipman,a,c Jason A. Robertsa,c
Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australiaa; Chemical Pathology, Pathology Queensland, Brisbane,
Queensland, Australiab; Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australiac
The use of therapeutic drug monitoring (TDM) to optimize beta-lactam dosing in critically ill patients is growing in popularity,
although there are limited data describing the potential impact of altered protein binding on achievement of target concentra-
tions. The aim of this study was to compare the measured unbound concentration to the unbound concentration predicted from
published protein binding values for seven beta-lactams using data from blood samples obtained from critically ill patients.
From 161 eligible patients, we obtained 228 and 220 plasma samples at the midpoint of the dosing interval and trough, respec-
tively, for ceftriaxone, cefazolin, meropenem, piperacillin, ampicillin, benzylpenicillin, and flucloxacillin. The total and un-
bound beta-lactam concentrations were measured using validated methods. Variabilities in both unbound and total concentra-
tions were marked for all antibiotics, with significant differences being present betweenmeasured and predicted unbound
concentrations for ceftriaxone and for flucloxacillin at the mid-dosing interval (P< 0.05). The predictive performance for calcu-
lating unbound concentrations using published protein binding values was poor, with bias for overprediction of unbound con-
centrations for ceftriaxone (83.3%), flucloxacillin (56.8%), and benzylpenicillin (25%) and underprediction for meropenem
(12.1%). Linear correlations between the measured total and unbound concentrations were observed for all beta-lactams (R2
0.81 to 1.00; P< 0.05) except ceftriaxone and flucloxacillin. The percent protein binding of flucloxacillin and the plasma albu-
min concentration were also found to be linearly correlated (R2 0.776; P< 0.01). In conclusion, significant differences be-
tweenmeasured and predicted unbound drug concentrations were found only for the highly protein-bound beta-lactams ceftri-
axone and flucloxacillin. However, direct measurement of unbound drug in research and clinical practice is suggested for
selected beta-lactams.
Infections are common in intensive care units (ICU), with over50% of patients considered infected at any one time (1). Mor-
bidity and mortality rates remain high among critically ill patients
with infection, and antibiotics are the single most effective inter-
vention for reducing mortality rates (2–7). Complicating the like-
lihood of achieving effective antibiotic therapy are the effects of
the complex disease processes that critically ill patients undergo
and the associated significant effects on antibiotic pharmacokinet-
ics (PK). For the commonly used family of antibiotics, the beta-
lactams, these PK changes, including those relating to altered pro-
tein binding, have been shown in numerous studies to result in
high proportions of critically ill patients manifesting subtherapeu-
tic or toxic concentrations when standard dosing approaches are
used (7–12). Given the association between therapeutic antibiotic
exposure and improved patient outcomes (13, 14), the use of ther-
apeutic drug monitoring (TDM) to optimize beta-lactam expo-
sures has been proposed as potentially useful for dose optimiza-
tion in critically ill patients (8, 15–18).
The existing reports for beta-lactam TDM have all used total
antibiotic concentrations for determining the need for dose ad-
justment, which is problematic given that the unbound concen-
tration of antibiotic is responsible for bacterial killing. The accu-
racy of such an approach is unclear. Given that hypoalbuminemia
occurs in approximately 40% of critically ill patients (19, 20), the
potentially negative effects of altered protein binding of beta-lac-
tam antibiotics may be common (21–24). It is likely that direct
measurement of unbound antibiotic concentrations should be
preferred to the calculation of unbound concentrations from pub-
lished protein binding values because such calculations may not
reflect the unbound beta-lactam plasma concentration in a criti-
cally ill patient and therefore reduces the likelihood of optimized
dosing. An understanding of protein binding of beta-lactams in
this challenging patient population is essential to ensure optimal
clinical dose adjustment.
Given the uncertainty regarding protein binding changes in
critically ill patients, the aim of this study was to compare the
measured unbound concentrations with the unbound concentra-
tions predicted from published protein binding values for seven
beta-lactam antibiotics (ceftriaxone, cefazolin, meropenem, pip-
eracillin, ampicillin, benzylpenicillin, and flucloxacillin).
MATERIALS AND METHODS
Patient selection. This observational study was conducted as part of a
beta-lactam TDM program for critically ill patients at a 27-bed tertiary
referral ICU. Beta-lactam TDM is provided as a part of routine clinical
care in this unit. Approval to collect these data was granted by the local
institutional review board (Royal Brisbane and Women’s Hospital Hu-
man Research Ethics Committee).
Ten antibiotics are included in the routine TDM service: ampicillin,
benzylpenicillin, dicloxacillin, flucloxacillin, piperacillin, ceftriaxone,
cephalothin, cefazolin, meropenem, and ertapenem (25, 27). Patients
were eligible for inclusion in this analysis if they were18 years old, were
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receiving one of the selected study antibiotic(s), and were expected to
remain on the treatment for the next 24 h. The empirical dosing regimen
and subsequent dose adjustment were undertaken by the treating physi-
cian in consultation with the clinical pharmacist.
Various demographic and clinical data were collected to describe the
patient sample, including age, gender, weight, and plasma albumin and
creatinine concentrations. Data for creatinine clearance on the sampling
day were also collected, which were estimated from plasma creatinine
concentrations by using the Cockcroft-Gault equation (26).
Sampling. As per the TDM protocol, blood samples were obtained at
the assumed PK “steady state,” defined as sampling after administration of
at least four prior doses. For intermittent dosing, two plasma samples
were obtained, the first one at the midpoint of the dosing interval and the
second one immediately prior to redosing (trough concentration). For
continuous infusion, plasma samples were taken after at least 4 half-lives.
Patients treated with more than one study antibiotic were eligible to pro-
vide more than one set of blood samples on the same day.
Beta-lactam assays. Plasma total and unbound concentrations of beta-
lactams were determined by using two different validated high-perfor-
mance liquid chromatography (HPLC) assays, which were reported pre-
viously (25, 27). Briefly, to measure total beta-lactam concentrations,
plasma samples were extracted with a known amount of internal standard
and deproteinated with acetonitrile. The supernatant was added to chlo-
roform, and the aqueous phase was analyzed by using HPLC. The concen-
tration ranges of the standard curves were 1 to 500 mg/liter for all antibi-
otics (except for meropenem [1 to 250 mg/liter]). The coefficients of
variation for interassay and intra-assay precision were 10%, and the
accuracy was within 6% for all antibiotics. To measure unbound drug
concentrations, plasma samples were filtered by using an Amicon Ultra
0.5-ml 30,000-molecular-weight-cutoff centrifugal filter device. The ul-
trafiltrates were mixed with morpholineethanesulfonic acid (MES) buffer
(pH 6.6) and analyzed by using HPLC. The concentration ranges of the
standard curves were 0.1 to 50 mg/liter for all antibiotics (except for pip-
eracillin [0.1 to 100 mg/liter]). The coefficients of variation for interassay
and intra-assay precision were 10%, and the accuracy was within 10%
for all antibiotics.
Calculation of unbound concentrations from total concentrations.
Unbound concentrations of antibiotics were calculated from total con-
centrations by using published percent binding data, as shown in Table 1.
In view of the saturable concentration-dependent protein binding kinet-
ics of ceftriaxone, unbound concentrations of ceftriaxone were calculated
from total concentrations (Ctot) by using the following equation (28):
Cfree
1
2(nP 1kaff  Ctot)(nP 1kaff  Ctot)2 4Ctotkaff 
where the capacity constant (nP) is 517 mol/liter and the binding affinity
constant (kaff) is 0.0367 liters/mol.
Statistics. All continuous data were reported as means and standard
deviations, or medians and interquartile ranges, as appropriate. Contin-
uous data were analyzed by using the Student t test. Correlation between
total and unbound antibiotic concentrations and covariations between
continuous demographic and clinical variables with antibiotic concentra-
tions and percentages of protein binding were determined by using linear
regression. Bland-Altman plots were constructed with GraphPad (version
6.0a; GraphPad Software Inc.) to assess the agreement between calculated
unbound beta-lactam concentrations and measured unbound concentra-
tions. Percent transformation was performed to increase the normality of
the data for the constructions of Bland-Altman plots, as evaluated by
Spearman’s rank correlation coefficient (). Bias, 95% limits of agree-
ment, and corresponding 95% confidence intervals were calculated as
previously described (29). P values of0.05 were considered significant.
RESULTS
One hundred sixty-one patients were eligible for analysis, and
their demographic and clinical characteristics are shown in Table
2. Patients were typically male and older than 50 years of age, with
a serum albumin concentration below the normal range on the
day of sampling. Renal function, as described by plasma creatinine
concentrations, was highly variable. Forty-two patients had TDM
performed on more than one occasion, and one patient received
two beta-lactams simultaneously. Two hundred twenty-eight and
220 mid-dosing and trough samples were assayed, respectively.
Due to the limited sensitivity of the assay for total concentrations
below 1 mg/liter, 3 mid-dosing-interval concentrations and 23
trough concentrations reported as 1 mg/liter were excluded
from the analysis. The total number of samples included in the
analyses described below was 422. Seventeen patients received
continuous renal replacement therapy (CRRT) on the day of sam-
pling.
The dosage ranges for the prescribed antibiotics are shown in
Table 3. Variabilities in dosing regimens and resultant concentra-
tions were observed, with marked deviations of predicted concen-
trations from the line of identity, in particular for piperacillin and
benzylpenicillin at both sampling times and for trough concentra-
tions of meropenem, ceftriaxone (Fig. 1a), and flucloxacillin.




binding (%) (range) Reference
Piperacillin 30 35
Meropenem 2 36
Ceftriaxone 89.5 (83–96) 37
Ampicillin 20 (15–25) 38
Cefazolin 80 (74–86) 39
Benzylpenicillin 65 40
Flucloxacillin 93 41
TABLE 2 Demographics and clinical characteristics of the studied
patientsa
Characteristic Value
% male patients 59.6
Mean age (yr) SD 52 17
Median plasma creatinine concn (mol/liter) (IQR) 69 (30–381)
Mean creatinine clearance (ml/min) SDb 131.9 75.4
Mean plasma albumin concn (g/liter) SD 24 6
Mean body wt (kg) SD 80.6 22.4
Mean BMI (kg/m2) SD 27.6 7.4
a Plasma creatinine and plasma albumin concentrations were measured on the day of
sampling; other parameters were measured upon admission. IQR, interquartile range;
BMI, body mass index.
b Creatinine clearance was estimated by using the Cockcroft-Gault formula.
TABLE 3 Dosage ranges for studied beta-lactams
Antibiotic Dosage range (mg)
Meropenem 500 every 12 h–2,000 every 6 h
Piperacillin-tazobactam 4,500 every 12 h–4,500 every 6 h
Ampicillin 1,000 every 8 h–1,000 every 6 h
Ceftriaxone 1,000 every 12 h–2,000 every 8 h
Cefazolin 1,000 every 8 h–2,000 every 8 h
Benzylpenicillin 1,200 every 4 h–2,400 every 4 h
Flucloxacillin 1,000 every 4 h–2,000 every 4 h
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Measured unbound concentrations tended to be higher than pre-
dicted for ceftriaxone at all concentrations and for piperacillin,
benzylpenicillin, and flucloxacillin especially at higher concentra-
tions. However, measured unbound concentrations were only sig-
nificantly higher (P 0.05) than predicted for ceftriaxone at both
sampling times and for flucloxacillin at the mid-dosing interval.
The percentage of unbound piperacillin was significantly higher at
the trough time point in patients receiving CRRT (82.5%, versus
69.6% for non-CRRT patients; P 0.01). No significant relation-
ship was observed for other studied beta-lactams.
A linear correlation between the measured and predicted un-
bound concentrations was established for all studied beta-lactams
except ceftriaxone and flucloxacillin. Linear regression correla-
tions between total and unbound concentrations described using
an R2 value were between 0.81 and 1.00 for beta-lactams (P 
0.001 for all except cefazolin [P  0.003]) (Fig. 1b). A nonlinear
correlation between the measured and predicted unbound con-
centrations was observed for flucloxacillin (R2  0.91).
The predictive performance of the calculated unbound beta-
lactam trough concentrations was assessed by Bland-Altman
plots, as shown in Fig. 2 and Table 4. Biases in calculated unbound
concentrations were observed for ceftriaxone, flucloxacillin, and
benzylpenicillin, where actual (measured) unbound concentra-
tions were underpredicted. For meropenem and cefazolin, the cal-
culated unbound concentrations were biased for overpredicting
unbound concentrations. The 95% limits of agreement for calcu-
lated unbound concentrations as a predictor of measured un-
bound concentrations were wide for the majority of studied beta-
lactams.
No significant associations were found between the percentage
of binding and albumin concentrations for any of the beta-lac-
tams studied except flucloxacillin (R2 0.76; P 0.01). For cefa-
zolin, the relationship between percentage of protein binding and
albumin concentrations was not analyzed due to inadequate albu-
min concentration data available for those subjects.
DISCUSSION
In this study of critically ill patients, we compared the observed
unbound concentration of beta-lactam antibiotics with the un-
bound concentration predicted by using published protein bind-
ing values. These data confirm the high variability and in some
cases the unpredictability of unbound beta-lactam concentrations
in critically ill patients. The present work is unique in terms of the
number of antibiotics studied and the evaluation of predictive
performance for calculating unbound beta-lactam concentrations
in critically ill patients by using published protein binding values.
The efficacy of beta-lactams has been well defined according to
the time that the unbound (or free) concentration exceeds the
MIC (fTMIC) of the bacterial pathogen. Traditionally, most as-
says used in PK studies of critically ill patients measure total beta-
lactam antibiotic concentrations and subsequently calculate un-
bound concentrations from published plasma protein binding
data that have been obtained from non-critically-ill patient
groups.
Since variations in protein binding and the prevalence of
hypoalbuminemia among critically ill patients have been observed
in other studies (21, 25, 30), there is increasing concern regarding
the accuracy of this estimation, especially for highly protein-
bound drugs in critically ill patients. Since the time course of un-
bound beta-lactam concentrations is more relevant than the total
concentration, direct measurement of the unbound fraction has
been suggested to have potential advantage in antibiotic dose op-
timization for critically ill patients. In this study, we utilized a
rapid and inexpensive assay for measurement of unbound beta-
lactam concentrations in clinical practice. The data presented
again demonstrate severely altered PK of beta-lactams in critically
ill patients.
As expected, in our cohort of critically ill patients with low
plasma albumin concentrations (mean, 24.5 g/liter), significant
differences between predicted (from total concentrations) and
measured unbound concentrations were found for the highly pro-
tein-bound antibiotics ceftriaxone and flucloxacillin. The mean
percentage of protein binding for ceftriaxone (87.3 to 87.7%) de-
termined in this study lies within the lower limits (83 to 96%)
found in healthy volunteers (31) yet is similar to that found in a
group of surgical critically ill patients (85.5 to 91.5%) (32). How-
ever, when we used a saturable model of ceftriaxone protein bind-
ing with published binding parameters to predict unbound con-
centrations from our total concentration data, the percentage of
protein binding was approximated to be around 95%, suggesting
an overestimation of protein binding by the model when applied
to our patient cohort. Nevertheless, no significant correlation be-
tween albumin concentrations and the unbound fraction of ceftri-
axone was found in this study. On the other hand, a correlation
between albumin concentrations and the unbound fraction was
found for flucloxacillin, as observed previously in cohorts of septic
neonates and adult critically ill patients, with both groups having
lower-than-normal plasma albumin concentrations (30, 33). Of
note, significant differences between measured and calculated un-
FIG 1 Linear correlation between measured and predicted unbound trough
concentrations of ceftriaxone (a) and cefazolin (b) (R2 0.96; P 0.003). The
x y plots are shown as gray dashed lines.
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bound flucloxacillin concentrations were found only at the higher
concentrations at the mid-dosing time point but not at the trough
time point. This may reflect the nonlinearity of protein binding at
high concentrations and, thus, poor prediction of unbound values
in this range.
A reduction of the unbound fraction for meropenem from
98% in healthy volunteers to a median of 90% was observed
among our patients. Despite this fact, there was no significant
difference between measured and predicted unbound mero-
penem concentrations, possibly due to its relatively low fraction of
FIG 2 Bland-Altman plots of relative difference (percentage of measured unbound concentrations) against the mean of predicted and measured unbound
concentrations for piperacillin (n 94; 	0.51; P 0.01) (a), ampicillin (n 8;  0.42; P 0.30) (b), benzylpenicillin (n 11; 	0.92; P 0.01) (c),
meropenem (n 49;   0.02; P 0.91) (d), ceftriaxone (n 19;  	0.43; P 0.07) (e), cefazolin (n 5;  	0.80; P 0.01) (f), and flucloxacillin (n
11;   	0.81; P 0.01) (g). The biases and 95% limits of agreement are shown as solid and broken horizontal lines, respectively.
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protein binding, where a small change in the percentage of bind-
ing would alter the unbound drug concentrations only minimally
(34, 42). Our data demonstrate that plasma protein binding of
beta-lactams in critically ill patients is highly variable, and a cor-
relation with albumin concentration exists only for selected
agents. Although linear correlations between total and unbound
concentrations exist for some of the studied beta-lactams, the pre-
dictive performance of calculated unbound concentrations was of
concern in terms of underdosing, especially for piperacillin at low
concentrations (50 mg/liter) and for meropenem, where un-
bound concentrations were consistently underpredicted at a lim-
ited but considerable magnitude. Another important finding from
this analysis was that for ceftriaxone, benzylpenicillin, and flu-
cloxacillin, the observed unbound concentration was higher than
the predicted concentration, meaning that dose adjustments
based on the low predicted unbound concentrations may not al-
ways be required. Dose adjustments for possible concentration-
related adverse events may also not be accurate in this context. The
unbound concentration assay used in this study is an inexpensive
and convenient means to overcome the limitation of predicting
unbound drug concentrations under these circumstances.
Limitations of the study. First, the variability of clinical con-
ditions and interventions that can vary beta-lactam PK in critically
ill patients as well as the small cohort of patients and small number
of samples available for the analysis of some antibiotics (namely,
cefazolin, benzylpenicillin, and flucloxacillin) could be consid-
ered limitations of this study. Nevertheless, this is the largest data
set of unbound measurements of these drugs. Second, the assay
used in this study has limited sensitivity for total beta-lactam con-
centrations of 1 mg/liter, such that conversion from total to
unbound concentrations was not established for this low concen-
tration range. Finally, the 95% limits of agreement determined by
Bland-Altman plots depend on the assumption that the differ-
ences between the two measurement methods are constant
throughout the range of measurements and follow a Gaussian
distribution. Although percent transformation (or logarithmic
transformation [data not shown]) improved the distribution of
our data, the percent differences between predicted and measured
unbound concentrations still significantly varied with the means
of the two measurements for benzylpenicillin, flucloxacillin, pip-
eracillin, and cefazolin. However, the analysis used provides suf-
ficient information on bias and precision of calculating unbound
concentrations from total measured concentrations to conclude
whether the predictive performance of the calculated unbound
concentrations is adequate in the clinical context.
In summary, this is the first paper that directly compares mea-
sured total and unbound beta-lactam antibiotic concentrations in
critically ill patients. We found a high variability in beta-lactam
concentrations and plasma protein binding in a cohort of critically
ill patients. A correlation between percent protein binding and
plasma albumin concentrations was observed only for flucloxacil-
lin. Given the variability of unbound beta-lactam concentrations
in critically ill patients and the clinical importance of unbound
drug concentrations, utilization of an inexpensive and convenient
assay for determination of unbound drug concentrations in re-
search and clinical practice is suggested.
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